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Treatment  of  genotype  one  hepatitis  C  virus  (HCV)
infection in  HIV  co-infected  patients  using
telaprevir based  regimen
Dear Editor,
Over 4 million individuals in the United States and over 170
million worldwide are living with hepatitis C virus (HCV).
Among HIV infected patients, the estimated HCV co-infection
rate can be as high as 25%.1
Prior to the approval of the direct-acting antivirals (DAA),
HCV treatment in HCV co-infected patients with pegylated
interferon and ribavirin (PIFN/RBV) had very low sustained
virological response (SVR) rates ranging from 7 to 29%.2,3 The
recently approved DAA-based HCV regimens have markedly
improved the SVR rate in HIV co-infected patients.4,5
Telaprevir is an oral DAA protease inhibitor (PI) approved
for treatment-naïve and treatment-experienced patients with
HCV genotype 1 infection.
At East Carolina University Infectious Diseases Clinic,
once DAA were approved for monoinfected HCV patients, all
genotype 1 HIV co-infected patients were started on telaprevir-
based regimen for HCV. Here, we present the efﬁcacy, safety
and tolerability of telaprevir-based therapy for HCV genotype
1 in 12 patients.
Twelve HIV/HCV-1 co-infected patients have been treated
with telaprevir-based therapy for HCV. Eight patients (66.7%)
were African-American. Eleven patients (92%) were on
HAART. One patient was long-term non-progressor. In all
except one, HIV therapy was switched to a regimen of
tenofovir–emtricitabine and raltegravir. All but one patient
(92%) were treatment-naïve for HCV therapy. Seven patients
(58%) had HCV genotype 1a, three (25%) had genotype 1b, and
two did not have subtype identiﬁcation. Eight patients (66.7%)
had a viral load greater than 800,000 IU/mL.
At week 4 of therapy, 12 patients (100%) achieved HCV viral
load <25 IU/mL. At week 12, 10 patients had viral load mea-
surement and of those 90% (9/10) had undetectable HCV viral
load. Three patients stopped therapy at weeks 5, 7, and 34,
respectively, because of side-effects (depression and severe
pancytopenia). One patient who received therapy for only ﬁve
weeks eventually attained SVR. Eight of the twelve patients
(66.7%) attained SVR six months after completing therapy.
There was only one case of viral breakthrough while on ther-
apy. The remaining three patients had undetectable viral load
when they stopped therapy either because of noncompliance(one patient) or side-effects (two patients). All three eventually
failed therapy.
The most common side-effects were anemia (100%),
thrombocytopenia (100%), neutropenia (58.3%), and skin rash
and itching (33.3%). Despite the need for dose adjustment, only
three patients had to discontinue therapy due to side-effects.
HIV viral load remained undetectable throughout the study
in all HIV infected patients who were on therapy. There was a
drop of CD4 count in all patients, but CD4 count remained
above 200 cells/mm3 and the drop was not clinically sig-
niﬁcant. Ten patients were switched to a raltegravir-based
regimen and all tolerated the regimen well.
HCV progresses faster in HIV co-infected patients and has
become a prominent cause of morbidity and mortality in
co-infected patients. Therapy for HCV genotype 1 with just
PIFN/RBV has been disappointing, with low SVR rates and thus
few patients were willing to consider therapy.3
In this study, out of 12 patients seven had HCV genotype
1a, eight were African American, and eight (66.7%) had high
viral loads. Despite multiple negative predictors, 8/12 (66.7%)
attained SVR and there was only one viral breakthrough while
on therapy. The results were comparable to the 74% SVR
rate in recently presented data.4 Three other patients failed
therapy due to early drug discontinuation secondary to non-
compliance or side-effects.
As predicted by the data from the monoinfected HCV stud-
ies, anemia was the most common side-effect. Recently, FDA
has approved 12-week DAA-based therapy for HIV/HCV co-
infection, and the recently updated AASLD/IDSA guideline on
HCV therapy also endorsed this short course regimen.5,6 Our
data, which showed the early clearance of HCV virus during
therapy, concur with these recommendations.
Ten out of 11 patients (91%) who were on HAART were
switched to a raltegravir–tenofovir–emtricitabine regimen
prior to staring HCV therapy. HIV viral load remained unde-
tectable in all patients throughout their HCV therapy.
In conclusion, the addition of DAAs to the treatment
of HCV genotype 1 among HIV/HCV co-infected patients
has shown a remarkable improvement in efﬁcacy without
compromising safety or compliance, nor increasing morbidity
or mortality. Our study is additional evidence to the growing
body of literature that shows comparable SVR rates between
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IV co-infected and HCV monoinfected patients when treated
ith DAA-based regimens. Recently approved and ongoing
tudies on HCV therapy will likely build on this already
chieved SVR rates while shortening treatment duration and
mproving adherence.
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